Long Circulation of PEG-TRAIL Improves Anti-Hepatic Fibrosis Effect of TRAIL Via Targeting Activated Hepatic Stellate Cells

Long Circulation of PEG-TRAIL Improves Anti-Hepatic Fibrosis Effect of TRAIL Via Targeting Activated Hepatic Stellate Cells

Background: The short half-life of TRAIL (tumor necrosis factor–related apoptosis-inducing ligand) greatly limits its clinical application. This study was aimed to improve its potency on liver fibrosis through PEG (polyethylene glycol) modification prolonging the half-life of TRAIL.Methods: PEG, TRA...

Full description

Bibliographic Details
Main Authors: Bingyun Lu, Lijun Peng, Shenggen Luo, Jing’e Zhou, Nan Xu, Chunxiu Dong, Zhiqiang Yan, Huiyi Li, Qinghua Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Materials
Subjects:
PEG
TRAIL
long circulation
hepatic fibrosis
hepatic stellate cells (HSCs)
LX-2
Online Access:https://www.frontiersin.org/articles/10.3389/fmats.2021.682844/full

Internet

https://www.frontiersin.org/articles/10.3389/fmats.2021.682844/full

Similar Items